Adhesion molecules and p16 expression in endocervical adenocarcinoma.
An immunohistochemical (IHC) study has been conducted on 34 cases of untreated endocervical adenocarcinomas collected among three institutions (Ospedale S. Andrea, Rome; Istituto Nazionale Tumori "Fondazione G. Pascale", Naples; and Clinica Malzoni, Avellino). The E-cadherin and alpha- and beta-catenin complex status has been investigated along with p16INK4a in all studied cases with the aim to study whether the pattern of expression of the cadherin-catenin complex could be causally related to the expression of P16INK4a protein. Results were evaluated for statistical significance by a non-parametric test (Kruskal-Wallis). Endocervical adenocarcinomas as a group were uniformly expressing p16INK4a except for two cases, and all lesions displayed downregulation of the cadherin-catenin complex, without demonstrating statistically significant differences among the different histotypes. The lack of nuclear accumulation of beta-catenin found in this group of lesions probably implies that no alteration of the beta-catenin/Wnt metabolic pathway is present in endocervical adenocarcinoma, as opposed to what is found in the literature for squamous carcinoma of the cervix. The diffuse expression of p16INK4a protein in this group of neoplasms stresses the important role of high-risk human papillomavirus infection in neoplastic causation possibly via the viral E7-mediated inactivation of pRB tumor-suppressor protein and also underlines the useful role of p16INK4a immunostaining in the diagnostic algorithm of endocervical adenocarcinomas. In consideration of these findings, investigation of downstream beta-catenin genes c-myc and cyclin D1 is sought as possibly contributive in the molecular pathogenesis of endocervical adenocarcinoma.
Carico
Elisabetta
E
U.O. Citopatologia, IIa Facoltà Medicina e Chirurgia La Sapienza, Rome, Italy.
Fulciniti
Franco
F
Giovagnoli
Maria Rosaria
MR
Losito
Nunzia Simona
NS
Botti
Gerardo
G
Benincasa
Giulio
G
Farnetano
Maria Giuseppina
MG
Vecchione
Aldo
A
D000230:Adenocarcinoma / Q000737:chemistry*; D000328:Adult; D000368:Aged; D015820:Cadherins / Q000032:analysis*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000737:chemistry*; D051178:alpha Catenin / Q000032:analysis*; D051176:beta Catenin / Q000032:analysis*
D015820:Cadherins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D051178:alpha Catenin; D051176:beta Catenin
Gynecol Oncol. 2000 Aug;78(2):97-105
10926787
Am J Surg Pathol. 2003 Feb;27(2):187-93
12548164
Virchows Arch A Pathol Anat Histopathol. 1992;421(2):149-56
1514246
Int J Cancer. 1994 Aug 1;58(3):393-9
7519585
Int Arch Med. 2008 Jul 07;1(1):10
18606007
Science. 2002 May 17;296(5571):1308-13
11964443
Anticancer Res. 2004 Nov-Dec;24(6):3843-50
15736420
J Pathol. 2003 Apr;199(4):471-8
12635138
J Pathol. 1995 Jun;176(2):151-9
7636625
Cancer Res. 1992 Apr 1;52(7):1981-7
1551127
Virchows Arch. 2001 Dec;439(6):725-51
11787845
Cancer Lett. 1996 May 15;103(1):11-7
8616803
Cancer. 2002 Feb 25;96(1):5-13
11836697
Oncol Rep. 2002 Sep-Oct;9(5):915-28
12168049
J Pathol. 1998 Jul;185(3):267-72
9771480
World J Surg Oncol. 2005 Jun 21;3:38
15969753
Curr Opin Cell Biol. 1993 Oct;5(5):806-11
8240824
Br J Cancer. 1995 Jan;71(1):166-72
7819034
J Cell Biol. 1991 Apr;113(1):173-85
2007622
Am J Clin Pathol. 1996 Apr;105(4):394-402
8604681
Cancer. 1996 Apr 15;77(8 Suppl):1605-13
8608551
Gynecol Oncol. 2001 Feb;80(2):156-61
11161853
Lancet Oncol. 2008 Oct;9(10):937-45
18783988
J Cell Biol. 1994 Jun;125(6):1327-40
8207061
Mol Carcinog. 1999 Jul;25(3):207-18
10411147
Histopathology. 2004 Aug;45(2):200-2
15279644
Melanoma Res. 1996 Apr;6(2):127-31
8791270
Infect Agent Cancer. 2007 Sep 06;2:16
17822553
Int J Pancreatol. 1996 Feb;19(1):25-30
8656024
Am J Pathol. 1996 May;148(5):1375-80
8623909
Int J Mol Med. 2001 Oct;8(4):353-8
11562771
J Cell Sci. 1993 Mar;104 ( Pt 3):751-62
8267793